-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153

Benzinga·07/22/2026 11:12:12
Listen to the news
Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $153.